XML 80 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Acquisitions - Acquisition of Raxibacumab Asset (Details) - Raxibacumab - USD ($)
$ in Millions
12 Months Ended
Oct. 02, 2017
Dec. 31, 2019
Business Acquisition [Line Items]    
Upfront payments $ 76.0  
Amount of payment for manufacturing related milestones 20.0  
Transaction costs $ 77.6  
Increase to contingent consideration liability   $ 10.0